Re: TD Zenith Capital Corp | Grey Market : ZHCLF
in response to
by
posted on
Oct 16, 2020 03:27PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
You are responding to a July message. Since then, I called them. Other folks have called them. And it appears they looked into it because they disconnected it from ZHCLF a couple months ago.